Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02750280 · ClinicalTrials.gov registry record · NA
A Longitudinal Study to Evaluate an Extracellular Matrix (MatriStem®) for the Treatment of Diabetic Foot Ulcers
A NA study of Neuropathic Diabetic Foot Ulcer, sponsored by Calvary Hospital, Bronx, NY.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT02750280 is a NA study of Neuropathic Diabetic Foot Ulcer that has completed, run by Calvary Hospital, Bronx, NY. The registered enrollment target is 17 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02750280, a NA study of Neuropathic Diabetic Foot Ulcer, has completed, sponsored by Calvary Hospital, Bronx, NY.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This ia a prospective controlled longitudinal study to evaluate the effects of MatriStem® plus standard local wound care versus standard local wound care alone in the treatment of diabetic foot ulcers (DFUs), as assessed by incidence of complete wound healing by 16 weeks and ulcer recurrence with a 2 year follow-up.
Conditions Studied
Interventions
- DEVICE MatriStem® [Urinary Bladder Matrix (UBM)]
- DEVICE Mepilex® [Silicone foam dressing]
Study Locations (1)
New York
- Calvary Hospital Center for Curative and Palliative Wound Care - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02750280
The ClinicalTrials.gov registry entry for NCT02750280 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calvary Hospital, Bronx, NY, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuropathic Diabetic Foot Ulcer appearing as the primary indexed condition, and to 2 interventions - of which MatriStem® [Urinary Bladder Matrix (UBM)] is the first listed.
NCT02750280 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02750280 about?
NCT02750280 is a clinical study titled "A Longitudinal Study to Evaluate an Extracellular Matrix (MatriStem®) for the Treatment of Diabetic Foot Ulcers". This ia a prospective controlled longitudinal study to evaluate the effects of MatriStem® plus standard local wound care versus standard local wound care alone in the treatment of diabetic foot ulcers (DFUs), as assessed by incidence of complete wound healing by 16 weeks and ulcer recurrence with a ...
What is the current status of trial NCT02750280?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2015-06. Estimated completion is 2015-12.
What conditions does trial NCT02750280 study?
This clinical trial studies the following conditions: Neuropathic Diabetic Foot Ulcer.
What interventions are being tested in trial NCT02750280?
The interventions under investigation include: MatriStem® [Urinary Bladder Matrix (UBM)] (DEVICE), Mepilex® [Silicone foam dressing] (DEVICE).
Who is sponsoring clinical trial NCT02750280?
This trial is sponsored by Calvary Hospital, Bronx, NY, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02750280 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.